Loading
Sequencing tumours and blood from 101 patients found that mutations in chromatin genes go with better survival and that tumour DNA can be found in the blood of 43% of patients with localised cancer, flagging relapse six and a half months before a scan.
Whole-exome analyses of 24 tumours and targeted genomic analyses of 77 were combined with non-invasive examination of tumour-specific mutations in the circulation. Somatic mutations in the chromatin-regulating genes MLL, MLL2, MLL3 and ARID1A were found in 20% of patients and associated with improved survival; alterations in genes with potential therapeutic utility were found in over a third of cases. Liquid biopsy showed detectable circulating tumour DNA at diagnosis in 43% of patients with localised disease, and detection after resection predicted clinical relapse and poor outcome, with recurrence detected by ctDNA 6.5 months earlier than by computed tomography.
The first demonstration that molecular residual disease can be read in pancreatic cancer and that it moves months ahead of the scan.
Shares Cell-free DNA (cfDNA), ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Resectable pancreatic ductal adenocarcinoma.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Cell-free DNA (cfDNA), Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center, Circulating tumour DNA (ctDNA), Resectable pancreatic ductal adenocarcinoma.
Shares Cell-free DNA (cfDNA), ctDNA MRD positivity (molecular residual disease after curative treatment), Circulating tumour DNA (ctDNA), Liquid biopsy (ctDNA).
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares ctDNA MRD positivity (molecular residual disease after curative treatment), Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.